Physician profile
William E Nibley
NPI 1437108974
$160,498.57
in general payments reported to CMS, 2019-2025
62 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $11K · 2021: $9,706 · 2022: $19K · 2023: $33K · 2024: $21K · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $11K · Honoraria: $9,930 · Food and Beverage: $5,357 · Travel and Lodging: $3,292 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,820.00 |
| Consulting Fee | $10,978.75 |
| Honoraria | $9,930.00 |
| Food and Beverage | $5,356.52 |
| Travel and Lodging | $3,292.08 |
| Education | $148.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $55,438.58 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $39,791.92 | 2022-2024 | Tazverik |
| Astrazeneca Pharmaceuticals Lp | $15,126.35 | 2019-2025 | Imfinzi |
| Cornerstone Specialty Network LLC | $12,290.00 | 2020-2024 | |
| Daiichi Sankyo INC. | $8,995.20 | 2020-2025 | Enhertu, Datroway |
| Ipsen Bioscience INC. | $5,590.00 | 2024 | Tazverik |
| Genzyme Corporation | $3,943.44 | 2021-2025 | |
| Seagen INC. | $3,403.01 | 2019-2025 | Tukysa |
| Beigene USA, INC. | $2,330.90 | 2021-2024 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $1,978.07 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Glaxosmithkline, LLC. | $1,855.57 | 2020-2023 | Ojjaara, Zejula, Jemperli |
| Blueprint Medicines Corporation | $1,480.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $1,114.05 | 2022-2023 | Libtayo |
| Coherus Oncology, INC. | $920.67 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $621.54 | 2019-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $594.69 | 2020-2025 | Perjeta, Phesgo, Kadcyla |
| Emd Serono, INC. | $576.97 | 2021-2023 | Bavencio |
| Pfizer INC. | $557.70 | 2019-2025 | |
| Epizyme, INC. | $525.47 | 2022 | |
| Janssen Biotech, INC. | $366.27 | 2021-2025 | Darzalex, Rybrevant, Erleada |
| Merck Sharp & Dohme LLC | $355.33 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $185.43 | 2021-2025 | Verzenio, Jaypirca |
| Abbvie INC. | $166.92 | 2020-2025 | |
| Beone Medicines USA, INC. | $155.43 | 2025 | Brukinsa |
| Tersera Therapeutics LLC | $148.12 | 2023-2025 | Zoladex, Quzyttir |
| Celgene Corporation | $136.19 | 2022-2025 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $127.14 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.94 | 2022-2024 | Gilotrif |
| Incyte Corporation | $113.89 | 2022-2025 | Jakafi, Monjuvi |
| Medtronic, INC. | $105.40 | 2022-2025 | Synchromedii, Osteocool Rf Ablation System |
| Intuitive Surgical, INC. | $99.05 | 2023 | Da Vinci Surgical System |
| Takeda Pharmaceuticals U.S.A., INC. | $94.95 | 2024-2025 | Fruzaqla, Iclusig |
| Sumitomo Pharma America, INC. | $86.26 | 2024-2025 | Orgovyx |
| Puma Biotechnology, INC. | $83.79 | 2024-2025 | |
| Eisai INC. | $80.13 | 2022-2025 | |
| Asd Specialty Healthcare, LLC | $73.66 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $69.37 | 2022-2023 | Imbruvica |
| Alexion Pharmaceuticals, INC. | $68.01 | 2024 | Ultomiris |
| Amgen INC. | $55.57 | 2021-2023 | Xgeva, Nplate, Vectibix |
| Astellas Pharma US INC | $52.18 | 2022-2023 | Padcev |
| Kite Pharma, INC. | $50.47 | 2023-2025 | |
| Myovant Sciences INC. | $45.77 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $45.03 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.62 | 2023-2025 | |
| Taiho Oncology, INC. | $43.30 | 2019 | |
| Genentech, INC. | $31.58 | 2022 | |
| Aveo Pharmaceuticals, INC. | $30.00 | 2024 | |
| Ethicon INC. | $29.89 | 2025 | Monarch Platform |
| Rigel Pharmaceuticals, INC. | $27.12 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Agios Pharmaceuticals, INC. | $25.31 | 2025 | Pyrukynd |
| Iovance Biotherapeutics, INC. | $24.20 | 2025 | Amtagvi |
| Exelixis INC. | $24.15 | 2024 | Cabometyx |
| Alnylam Pharmaceuticals INC. | $23.71 | 2025 | Givlaari |
| Springworks Therapeutics, INC. | $23.41 | 2024 | Ogsiveo |
| Adc Therapeutics America, INC. | $22.06 | 2025 | |
| Deciphera Pharmaceuticals INC. | $20.57 | 2025 | Qinlock, Romvimza |
| Syndax Pharmaceuticals, INC. | $20.12 | 2025 | Revuforj |
| Sobi, INC | $19.26 | 2024 | |
| Apellis Pharmaceuticals, INC. | $18.59 | 2024 | Empaveli |
| Morphosys, US INC. | $16.23 | 2022 | |
| Stemline Therapeutics INC. | $14.92 | 2025 | Orserdu |
| Genmab U.S., INC. | $14.10 | 2025 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,970.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Nibley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.